Tenet Healthcare enters its July 24 earnings window with short interest climbing sharply and options traders still leaning defensive — a combination that makes the positioning story more interesting than the price action alone would suggest.
Short interest has jumped 69% over the past month, reaching 4.5% of the free float by June 30. The move accelerated notably around mid-June, when borrowed shares crossed back above 3.4 million after sitting closer to 2.5 million through late May. That's a meaningful rebuild in bearish positioning, even if the absolute level remains moderate. Cost to borrow has tracked higher alongside it, rising 56% on the week to 0.66% — still low in absolute terms, but the direction of travel is clear. Borrow conditions in the lending pool remain extremely loose, with availability running near 4,800% of short interest, meaning new shorts face essentially no friction entering positions. The lending market is not yet a headwind for bears.
Options tell a related story. The put/call ratio hit 1.72 on June 22 — the highest reading of the past year — before easing back to 1.19 by June 30. That pull-back in the ratio coincides with the stock's 3.4% weekly gain to $187.08, suggesting some defensive hedges are being unwound as price recovers. The z-score has nearly normalised to flat against the 20-day mean, so acute options stress has passed for now. What remains is a market that spent most of June building downside protection on this name.
The Street is broadly constructive but has been trimming targets. The direction of travel in analyst revisions has been uniformly lower since the April earnings print, with most covering firms maintaining Buy or Overweight ratings while cutting numbers — a "we still like it, but less so" posture. The mean price target sits near $243, implying roughly 30% upside from current levels, but the range has compressed from the mid-$270s to the low $200s in some cases. TD Cowen, the most recent mover, cut to $233 from $242 on June 22 while keeping its Buy. The bull case centres on the USPI ambulatory surgery segment, where margins and returns run ahead of the acute-care hospital business. The bear case is harder to dismiss: expiring ACA subsidies could remove coverage for the bulk of exchange-plan patients, with analysts modelling up to a $220 million headwind to the acute segment in 2026. At roughly 10x earnings and 6.8x EV/EBITDA, the valuation is not demanding, but that multiple assumes the subsidy cliff is manageable. The EPS surprise factor score ranks in the 90th percentile, reflecting a strong recent beat history.
Peer performance adds some texture. HCA added just 0.8% on the week while UHS gained 1.9% — both more modest than THC's 3.4% move. CYH and ACHC ran harder, up 8.4% and 20.3% respectively, but those moves likely reflect stock-specific catalysts rather than a sector-wide re-rating. Tenet's outperformance relative to the closest large-cap peer is a positive signal, but the gap versus a year-to-date laggard context means recovery framing is more appropriate than breakout framing.
With Q2 results due July 24, the setup is straightforward: the subsidy headwind is already on the Street's model, and the stock's prior quarterly reaction — a 1.8% drop on the day followed by a 6.5% decline over five days after the May print — sets a recent reference point. The question Q2 will answer is whether the subsidy drag lands inside or outside consensus estimates, and whether USPI volume trends are absorbing enough of that pressure to keep full-year guidance intact.
See the live data behind this article on ORTEX.
Open THC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
